Income From TAP Will Increase “Every Quarter” In 2005, Abbott Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott expects the TAP joint venture with Takeda will post sequential growth every quarter in 2005 as Prevacid (lansoprazole) and Lupron (leuprolide) gain steam throughout the year